Literature DB >> 3126809

Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein.

G R Castro1, C J Fielding.   

Abstract

Cultures of human skin fibroblasts were labeled to high cholesterol specific activity with [3H]cholesterol and incubated briefly (1-3 min) with normal human plasma. The plasma was fractionated by two-dimensional agarose-polyacrylamide gel electrophoresis and the early appearance of cholesterol label among plasma lipoproteins determined. A major part of the label at 1-min incubation was in a pre-beta-migrating apo A-I lipoprotein fraction with a molecular weight of ca. 70,000. Label was enriched about 30-fold in this fraction relative to its content of apo A-I (1-2% of total apo A-I). The proportion of label in this lipoprotein was strongly correlated with its concentration in plasma. Further incubation (2 min) in the presence of unlabeled cells demonstrated transfer of label from this fraction to a higher molecular weight pre-beta apo A-I species, to low-density lipoprotein, and to the alpha-migrating apo A-I that made up the bulk (96%) of total apo A-I in plasma. The data suggest that a significant part of cell-derived cholesterol is transferred specifically to a pre-beta-migrating lipoprotein A-I species as part of a cholesterol transport transfer sequence in plasma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126809     DOI: 10.1021/bi00401a005

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  76 in total

Review 1.  Tangier disease as a test of the reverse cholesterol transport hypothesis.

Authors:  A R Tall; N Wang
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini.

Authors:  Ivano Eberini; Laura Calabresi; Robin Wait; Gabriella Tedeschi; Angela Pirillo; Lina Puglisi; Cesare R Sirtori; Elisabetta Gianazza
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

3.  Alpha-helical requirements for free apolipoproteins to generate HDL and to induce cellular lipid efflux.

Authors:  H Hara; H Hara; A Komaba; S Yokoyama
Journal:  Lipids       Date:  1992-04       Impact factor: 1.880

4.  An integrated approach for the mechanisms responsible for atherosclerotic plaque regression.

Authors:  Andrew A Francis; Grant N Pierce
Journal:  Exp Clin Cardiol       Date:  2011

Review 5.  Metabolism of high density lipoproteins in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Chang-Ping Wu
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

Review 6.  The metabolism and anti-atherogenic properties of HDL.

Authors:  Kerry-Anne Rye; Christina A Bursill; Gilles Lambert; Fatiha Tabet; Philip J Barter
Journal:  J Lipid Res       Date:  2008-11-24       Impact factor: 5.922

Review 7.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

8.  Effects of site-directed mutagenesis at residues cysteine-31 and cysteine-184 on lecithin-cholesterol acyltransferase activity.

Authors:  O L Francone; C J Fielding
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

9.  Decreased activity of lecithin:cholesterol acyltransferase and hepatic lipase in chronic hypothyroid rats: implications for reverse cholesterol transport.

Authors:  Martha Franco; Graciela Castro; Luis Romero; Juan Carlos Regalado; Aida Medina; Claudia Huesca-Gómez; Serafín Ramírez; Luis F Montaño; Carlos Posadas-Romero; Oscar Pérez-Méndez
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

10.  Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in syrian hamsters.

Authors:  I Hardardóttir; A H Moser; J Fuller; C Fielding; K Feingold; C Grünfeld
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.